Day 4 Recap: Fall Clinical 2025

To stay informed with the latest conference insights, follow us on social media and subscribe to receive our eNewsletters.

Integrating GLP-1 Therapy, Advancing CSU Care, and Expanding Access

At Fall Clinical 2025, Marc Serota, MD, discussed how GLP-1 therapies, new CSU treatments, and hybrid care models are reshaping dermatologic practice heading into 2026.

Clinical Trials Offer a ‘Win-Win’ for Patients and Progress

Lio believes that collaboration between science and industry is vital for translating research into meaningful patient benefits.

Aaron Farberg, MD, Explains Gene Profiling in Atopic Dermatitis

Gene expression profiling may allow clinicians, according to Farberg, to predict patient responses to targeted treatments.

“From Injectable to Ingestible:” TYK2 Inhibitors for PsO and the Ongoing Challenge of PPP

At Fall Clinical 2025, Ron Vender, MD, discussed the evolving psoriasis treatment landscape and the persistent challenge of managing palmoplantar pustulosis.

Second Generation TYK2 Inhibitors Transform Psoriasis Management

Benjamin Lockshin, MD, noted long half-life biologics may allow patients to maintain remission with minimal injections.

Our editors are on site and ready to gather your insights, both as a presenter or as an attendee! Reach out to us at DTEditor@mmhgroup.com for the opportunity to speak with one of our editors. Stay tuned to Dermatology Times all weekend for exclusive conference coverage and expert insights.